Neurotensin Receptor 1 Is Expressed in Gastrointestinal Stromal Tumors but Not in Interstitial Cells of Cajal

Petra Gromova1, Brian P. Rubin2, An Thys1, Christophe Erneux3, Jean-Marie Vanderwinden1*

1 Laboratory of Neurophysiology, Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium, 2 Anatomic Pathology and Molecular Genetics, Cleveland Clinic, Lerner Research Institute and Taussig Cancer Center, Cleveland, Ohio, United States of America, 3 Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium

Abstract

Gastrointestinal stromal tumors (GIST) are thought to derive from the interstitial cells of Cajal (ICC) or an ICC precursor. Oncogenic mutations of the KIT or PDGFRA receptor tyrosine kinases are present in the majority of GIST, leading to ligand-independent activation of the intracellular signal transduction pathways. We previously investigated the gene expression profile in the murine KitK641E GIST model and identified Ntsr1 mRNA, encoding the Neurotensin receptor 1, amongst the upregulated genes. Here we characterized Ntsr1 mRNA and protein expression in the murine KitK641E GIST model and in tissue microarrays of human GIST. Ntsr1 mRNA upregulation in KitK641E animals was confirmed by quantitative PCR. Ntsr1 immunoreactivity was not detected in the Kit positive ICC of WT mice, but was present in the Kit positive hyperplasia of KitK641E mice. In the normal human gut, NTSR1 immunoreactivity was detected in myenteric neurons but not in Kit positive ICC. Two independent tissue microarrays, including a total of 97 GIST, revealed NTSR1 immunoreactivity in all specimens, including the Kit negative GIST with PDGF mutation. NTSR1 immunoreactivity exhibited nuclear, cytoplasmic or mixed patterns, which might relate to variable levels of NTSR1 activation. As studies using radio-labeled NTSR1 ligand analogues for whole body tumor imaging and for targeted therapeutic interventions have already been reported, this study opens new perspectives for similar approaches in GIST.

Citation: Gromova P, Rubin BP, Thys A, Erneux C, Vanderwinden J-M (2011) Neurotensin Receptor 1 Is Expressed in Gastrointestinal Stromal Tumors but Not in Interstitial Cells of Cajal. PLoS ONE 6(2): e14710. doi:10.1371/journal.pone.0014710

Editor: Patrick Callaerts, Katholieke Universiteit Leuven, Belgium

Received May 11, 2010; Accepted January 29, 2011; Published February 18, 2011

Copyright: © 2011 Gromova et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: National Fund for Scientific Research (Belgium) http://www2.frs-fnrs.be/, Televie grant 7.4.558.07.F, jointly to JMV and CE. National Fund for Scientific Research (Belgium), Fonds de la Recherche Scientifique Medicale grant 3.4.571.07.F to JMV. National Fund for Scientific Research (Belgium), Grant 7.4.529.08.F and Belgian State Policy http://www.belspo.be/belspo/home/port_en.stm PAIP (P6/28) to CE. BPR is funded by a generous grant from The Life Raft Group http://www.liferafgroup.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jmvdwin@ulb.ac.be

Introduction

Gastrointestinal stromal tumors (GIST) are the most common sarcoma of the gastrointestinal tract. They are thought to derive from the interstitial cells of Cajal (ICC) or an ICC precursor. Approximately 85% of GIST harbor oncogenic KIT mutations and 7% contain oncogenic platelet-derived growth factor receptor alpha (PDGFRA) mutations. KIT and PDGFRA are members of the type III receptor tyrosine kinase family. Oncogenic mutation of KIT or PDGFRA lead to constitutive autophosphorylation, ligand-independent activation of the downstream signal transduction pathways and subsequent deregulation of cell proliferation, survival and migration [1,2]. Since the release of imatinib mesylate (a.k.a. STI571, Gleevec™), an inhibitor of KIT and PDGFRA activation, the immunohistochemical demonstration of KIT immunoreactivity (-ir) has been essential for the diagnosis of GIST [3]. However, up to 15% of GIST show weak or negative staining for KIT [4]. Many of these “KIT-negative” GIST harbor PDGFRA mutations and may correspond to imatinib treatment [5,6], hence need to be classified correctly. Recently, Discovered on GIST-1 (DOG1, a.k.a. anoctamin, ANO1), Protein kinase C theta (PKC theta) and Carbonic anhydrase II (CAII) have been suggested as additional diagnostic markers and/or putative therapeutic targets [7–10]. Noteworthy, these genes are also expressed in normal KIT-ir ICC [7,10,11] and belong to the gene expression profile of KIT-ir ICC in the mouse small intestine [12]. Their presence in GIST thus likely reflects the fact that these tumors arise from the lineage of KIT-ir ICC.

We have recently identified genes expressed in GIST, but not in normal KIT-ir ICC, by comparing gene expression profiles of the antrum of transgenic mice harboring the oncogenic Kit K641E mutation [13] and WT littermates, using cDNA microarray. The G-protein-coupled receptor (GPCR), Neurotensin receptor 1 (Ntsr1) appeared highly upregulated in KitK641E antrum [14], while it did not belong to the gene expression profile of normal Kit-ir ICC in the mouse small intestine [12]. As studies using radio-labeled NTSR1 ligand analogues have already been reported for whole body tumor imaging and for therapeutic interventions [15], NTSR1 appeared as an interesting prospect. Hence we have characterized Ntsr1 expression in the murine KitK641E GIST model, in the normal human gut wall and in human GIST. NTSR1-ir was not detected in normal Kit-ir ICC, but was present in all GIST investigated, including Kit negative GIST harboring PDGFRA mutations.

Materials and Methods

The KitK641E murine model of GIST

A knock-in KitK641E murine model of GIST used in this study has been previously described [13]. Two weeks old (P14) KitK641E/K641E,
**Table 1. List of primers.**

### Primers for RT-PCR (human sequence)
- NM_006183.3 NT/N F 5'-AGGGCTTTTCAACACTGGGAG-3'
- NM_002531.2 NTSR1 R 5'-CCATACACGTGGCGTTCACA-3'
- NM_001101.3 β-actin R 5'-GAGCGCCGATCCACAC-3'

### Primers for q-PCR (murine sequence)
- NM_018766.2 Ntsr1 F 5'-CAAGGCTCGATCCACGTATGG-3'
- NM_008747.2 Ntsr2 F 5'-CTGGACGCTCCGCTTTGTGG-3'
- NM_019972.2 Ntsr3 F 5'-GCCGACGATGGGAGTAATC-3'
- NM_008084.2 Gapdh F 5'-GGATGAGCAGTGGACTCCGT-3'
- NM_007393.3 β-actin F 5'-AACCGTGAAAGGATGACCCAGAT-3'
- NM_002531.2 NTSR1 R 5'-GTTGATGGTGGAGCTGACGTAG-3'

**Table 2. Clinicopathologic features of the Cleveland Clinic GIST TMA.**

| Primary tumor site | Total (n) |
|--------------------|-----------|
| Gastric            | 34        |
| Small bowel        | 9         |
| Colon              | 2         |
| Rectovaginal       | 1         |
| Disseminated       | 3         |
| Risk category      | Total (n) |
| Malignant          | 7         |
| High risk          | 10        |
| Moderate risk      | 13        |
| Low risk           | 8         |
| Very low risk      | 6         |
| No risk            | 5         |
| Mitotic figures    | Total (n) |
| ≤5/50 HPF          | 26        |
| >5/50 HPF          | 17        |
| N.A.               | 6         |
| Mutation Status    | Total (n) |
| KIT mutation       | 25        |
| KIT exon 9 AY 502-503 duplication | 4 |
| KIT exon 11 duplication | 3 |
| KIT exon 11 deletion | 6 |
| KIT exon 11 deletion - MYE5 551-555 | 1 |
| KIT exon 11 deletion - PMYE 551-555 | 1 |
| KIT exon 11 V559D | 6 |
| KIT exon 11 V560D | 1 |
| KIT exon 11 V600D | 1 |
| KIT exon 11 W557G | 1 |
| KIT exon 13 K642E | 1 |
| PDGF mutation      | 9         |
| PDGFRα exon 12 - V561D | 2 |
| PDGFRα exon 12 deletion | 1 |
| PDGFRα exon 18 D842V | 4 |
| PDGFRα exon 18 D842Y | 1 |
| PDGFRα exon 18 Ins-Del | 1 |
| Wild type          | 11        |
| N.A.               | 4         |

**KIT-ir Total (n)**
- positive 44
- negative 4
- N.A. 1

**Table 1.**

| Primers for q-PCR (murine sequence) |
|--------------------------------------|
| Ntsr1 F 5'-CAAGGCTCGATCCACGTATGG-3' |
| Ntsr2 F 5'-CTGGACGCTCCGCTTTGTGG-3' |
| Ntsr3 F 5'-GCCGACGATGGGAGTAATC-3' |
| Gapdh F 5'-GGATGAGCAGTGGACTCCGT-3' |
| β-actin F 5'-AACCGTGAAAGGATGACCCAGAT-3' |
| β-actin R 5'-GAGCGCCGATCCACAC-3' |

**Table 2.**

| Tumor morphology | Total (n) |
|------------------|-----------|
| Spindle          | 35        |
| Epithelioid      | 14        |
| N.A.             | 6         |

**Footnote:** N.A.: data not available

**DOI:** 10.1371/journal.pone.0014710.t001

**DOI:** 10.1371/journal.pone.0014710.t002

**KNT/K414F and Knt/K414F littersmates, as well as adult (3-6 month old) Knt/K414F and Knt/K414F animals, were used.** Mice were bred and experiments performed in accordance with the ethics committee for animal well-being of the Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.

**RNA Extraction and PCR.** Total RNA was extracted from mouse antrum using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions as described [14]. Genomic DNA was removed with the DNA-free™ kit (Ambion, Inc., Austin, Texas). RNA (1 μg) was reverse transcribed with 200 units of M-MLV Reverse Transcriptase (Invitrogen, Eugene, Oregon) in a reaction containing random primers (Amersham Bioscience, Piscataway, NJ). For reverse transcription PCR (RT-PCR) the cDNA reverse transcription product was amplified with specific primers (Table 1) using 1U Taq DNA polymerase (Qiagen, Valencia, CA) according to the manufacturer’s instructions, during 40 cycles of 94°C for 30 sec, 57°C for 45 sec and 72°C for 45 sec. PCR products were separated on 2% agarose gel, stained with ethidium bromide and photographed under UV illumination. Real time quantitative PCR (qPCR) was performed as described [14], using SYBR Green chemistry on a 7500 Real time PCR system (Applied Biosystems, Foster City, CA). Identical conditions, namely 95°C for 10 min; then 40 cycles of 95°C for 15 sec and 60°C for 1 min were used for all primer sets (Table 1). Transcriptional quantification relative to Gapdh and β-actin housekeeping genes was performed using Qbase™ software [16]. Data were reported as the mean of three independent experiments and presented as normalized relative quantities (NRQ). Statistical analysis was performed in Microsoft Office Excel™ 2003 using unpaired Student’s t-test. Differences were regarded as statistically significant when p≤0.05.
rabbit NTR1 (H-130); 1:100 and goat Kit (C-14); 1:500 (Santa Cruz Biotechnology, Inc., Santa Cruz, Ca), rinsed twice in TBS and incubated in the dark for 1 hour at RT in TBS containing the secondary antibodies anti rabbit biotinylated; 1:200 [Jackson Immunoresearch, Cambridge, UK] and anti goat Alexa TM 488 conjugated; 1:200 (Invitrogen, Eugene, Oregon). Slides were then rinsed twice in TBS and incubated in the dark for 1 hour at RT with streptavidin-coupled NorthernLight TM 557 (NL557) (R&D Systems, Abingdon, Oxon, UK) in TBS. Secondary antibodies anti rabbit DyLight TM 549 conjugated; 1:200 [Jackson Immunoresearch, Cambridge, UK] were used for GIST882 cells immunolabeling.

The optimal working dilution was determined empirically for each antibody. The protocol used for double immunofluorescence staining did not modify the distribution or the intensity of each individual labeling observed in corresponding single procedures. Omission of the primary or of the secondary antibodies resulted in the absence of the respective fluorescent signal.

Nuclei were stained with 5 μM Hoechst in Tris-HCl (Merck-Belgolabo, Overijsse, Belgium) 0.05M (pH 7.4); containing 0.5 mg/ml type 1-AS Ribonuclease A for 5 min in the dark at RT.

After three rinses in TBS, preparations were mounted with Fluor Save TM Reagent anti-fade mounting medium (Calbiochem, Nottingham, UK).

Confocal microscopy. Preparations were viewed under a LSM 510 NLO multiphoton confocal microscope fitted on an Axiovert M200 inverted microscope equipped with a C-Apochromat 40×/1.2 N.A. water immersion objective (Zeiss, Iena, Germany).

The 543 nm excitation wavelength of the HeNe1 laser, a main dichroic HFT 488/543/633 and a long-pass emission filter (LP560 nm) were used for selective detection of the red fluorochrome. The nuclear stain Hoechst was excited in multiphotonic mode at 760 nm with a Mai Tai TM tunable broad-band laser (Spectra-Physics, Darmstad, Germany) and detected using a main dichroic HFT KP650 and a band-pass emission filter (BP435–485 nm).

Single optical sections, 2 μm thick, were collected for each fluorochrome sequentially. The images generated (pixel size: 0.1 μm) were merged and analyzed with the Zeiss LSM510 software and exported in .jpg image format.

Epifluorescence microscopy. Slides were examined under an AxioImager Z1 (Zeiss, Oberkochen, Germany) equipped with a Plan-Neofluar 40×/0.75 N.A. dry objective and band-pass filter HFT KP650 and a band-pass emission filter (BP435–485 nm).

Table 3. Clinicopathologic features of the SuperBiochips GIST TMA.

| Sex/Age average | Total in/years |
|-----------------|---------------|
| Male            | 28/58.3       |
| Female          | 20/62.6       |

| Primary tumor site | Total (n) |
|-------------------|-----------|
| Gastric           | 22        |
| Small bowel       | 15        |
| Abdominal cavity  | 1         |
| Rectum            | 2         |
| Disseminated      | 8         |

| Risk category | Total (n) |
|---------------|-----------|
| Malignant     | 8         |
| High risk     | 24        |
| Intermediate risk | 8     |
| Low risk      | 8         |

| Mitotic Figures | Total (n) |
|-----------------|-----------|
| ≤5/50           | 22        |
| >5/50           | 26        |

| KIT-ir | Total (n) |
|--------|-----------|
| positive | 48 |
| negative | 0 |

doi:10.1371/journal.pone.0014710.t003
before use, 5 µl of 30% H₂O₂ (Merck, Darmstadt, Germany) was added.

Staining was regarded as positive when specific (i.e. above background) NTSR1-ir signal was present in ≥10% of tumor cells. The pattern of subcellular distribution of NTSR1-ir was recorded as: nuclear (without distinct cytoplasmic staining), cytoplasmic (without distinct nuclear staining), or mixed. χ² (chi-squared), Fisher’s exact test and Student’s t-test, were used to test possible association between Ntsr1-ir and the clinico-pathological features of the tumors.

Human GIST882 cell line

The human GIST cell line GIST882 [19] was kindly provided by Dr. Jonathan A. Fletcher, Harvard Medical School, Boston, Massachusetts, USA. Cells were cultured at 37°C in DMEM (GIBCO, California USA) supplemented with 10% fetal bovine serum (FBS), 2% Penicillin/Streptomycin. Cells were starved overnight in minimal medium (i.e. without FBS), before stimulation with the NTSR1 agonist JMV449 (10 µM) (Tocris Bioscience, Ellisville, MO) for 4 hours.

Western blotting (WB).

Cells were lysed in buffer containing 10 mM Tris-HCl [pH 7.5], 150 mM KCl, 100M NaF, 0.5% Nonidet P-40, 12µM B-mercaptoethanol and 20 µl/ml proteases inhibitor mixture (Roche; Mannheim, Germany). Proteins were solubilized in sample buffer, heated at 95°C for 5 min, separated by SDS-PAGE on 8% polyacrylamide gel and transferred on a 0.2 µm nitrocellulose membrane. Primary anti-NTSR1 antibody (C-20); 1:100 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), secondary anti-goat IgG DyLight800 antibody; 1:10000 (Pierce, Thermo Fisher Scientific, Erembodegem, Belgium) and the Odyssey™ imaging system (LI-COR Biotechnology, Lincoln, NE) was used to reveal the signal.

Results

Ntsr1 expression in murine KitK641E GIST model

Ntsr1 mRNA expression is up-regulated in KitK641E antrum. Relative expression of Ntsr1 mRNA was markedly increased in KitK641E/K641E homozygous compared to KitWT/WT littermates (NRQ = 48.7; p = 7.7e-6) while Ntsr1 expression in heterozygous KitWT/K641E animals did not differ significantly from their KitWT/WT littermates. Three animals of each genotype were used for quantification. Data are reported as the mean ± SEM and presented as normalized relative quantities (NRQ), (**) p < 0.005.

B: In adult antrum, expression of Ntsr1 mRNA was moderately increased in KitWT/K641E heterozygous compared to KitWT/WT littermates. Three animals of each genotype were used for quantification. Data are reported as the mean ± SEM and presented as normalized relative quantities (NRQ), (*) p < 0.05.

C: Representative single confocal images of Ntsr1-ir distribution in the P14 mouse antrum: Ntsr1-ir (NL559, red) was observed in the Kit-ir (Alexa 488, green) hyperplastic layer of P14 homozygous KitK641E/K641E antrum (lower row) but was not present in the Kit-ir ICC in WT littermates (upper row). Ntsr1-ir was also consistently found in the myenteric plexus (white arrows) and intramuscular nerve fibers in all genotypes. Scale bar: 20 microns. Fluorescence intensity plots along the yellow lines illustrate the respective distribution of Ntsr1-ir (NL559, red) and Kit-ir (Alexa 488, green).

doi:10.1371/journal.pone.0014710.g001
expression in heterozygous $K_\text{WT}^{+/K641E}$ P14 animals was similar to their WT $K_\text{WT}^{+/+}$ littermates (Fig. 1A). $K_\text{WT}^{+/K641E}$ heterozygous compared to $K_\text{WT}^{+/+}$ littermates was moderate, but significant (NRQ = 2.9; $p = 0.049$) (Fig. 1B).

Ntr2 transcript was detected neither in $K_\text{WT}^{+/K641E}$ homozygous P14 antrum nor in $K_\text{WT}^{+/+}$ littermates. Relative Nts2 mRNA expression did not differ in $K_\text{WT}^{+/+/}$ homozygous P14 antrum compared to $K_\text{WT}^{+/+}$ littermates ($p = 0.33$) (data not shown).

Ntsr1-ir is not present in WT ICC. Ntsr1-ir was observed in the myenteric plexus and intramuscular nerve fibers in P14 $K_\text{WT}^{+/+}$ (Fig. 1C upper row), as well as in adult $K_\text{WT}^{+/+}$ animals (Fig. S1). Conversely, ICC, identified by Kit-ir, were consistently negative for Ntsr1-ir in WT animals.

Ntsr1-ir is expressed in the hyperplastic layer of Kit-ir cells in KitK641E antrum. In the antrum of P14 $K_\text{WT}^{+/K641E}$ animals, Ntsr1-ir decorated the Kit-ir hyperplastic layer (Fig. 1C bottom row), while in P14 $K_\text{WT}^{+/K641E}$ heterozygous antrum, Ntsr1-ir did not differ from P14 WT animals (data not shown). In adult heterozygous $K_\text{WT}^{+/K641E}$ animals, Ntr1-ir was detected also in hyperplastic clusters of Kit-ir cells but not in individual Kit-ir ICC without sign of hyperplasia (Fig. S1). In all genotypes, myenteric plexus and intramuscular nerve fibers consistently exhibited Ntsr1-ir.

NTSR1 expression in human GIST

NTSR1-ir is not present in human KIT-ir ICC. In the normal human colon, NTSR1-ir was detected in MP but not in the adjacent KIT-ir ICC (Fig. 2 upper row). Omission of primary antibody completely wiped out the signal and background (non-specific) signal in other cell types was minimal.

In a human GIST with $KIT$ K642E mutation, NTSR1-ir was present only in the KIT-ir tumor cells (Fig. 2 bottom row).

NTSR1-ir is present in human GIST irrespective to the mutation status. Immunohistochemistry for NTSR1 was performed on two independent TMA including a total of 97 GIST, 95 samples were considered for analysis, 2 spots were excluded due to poor quality of tissue. Clinico-pathological characteristics of the GIST cases are summarized in Tables 2 and 3.

All GIST stained positively for NTSR1-ir (Fig. 3A left and Fig. 3B). In adjacent non-tumoral tissue, NTSR1-ir was present in myenteric plexus but not in other cell types (Fig. 3A middle and right, respectively). Background (non specific) signal in non-tumoral tissue was minimal, confirming the specificity of the NTSR1-ir signal observed on TMA.

Noteworthy, 4 KIT negative GIST with PDGFR4 mutation were positive for NTSR1 staining (Fig. 3B). All 4 cases were of gastric origin, 3/4 showed epithelioid morphology and belong to the low-moderate risk category (Table 4).

Three patterns of NTSR1-ir were observed (Fig. 4): nuclear, without distinct cytoplasmic staining (Fig. 4A); cytoplasmic, without distinct nuclear staining (Fig. 4B); and mixed staining pattern, with NTSR1-ir present in nucleus as well as in cytoplasm (Fig. 4C). Mixed and nuclear staining were occasionally encountered in close vicinity (Fig. 4D) and were regarded as mixed patterns. A majority of GIST (63/95) showed mixed (nuclear + cytoplasmic) NTSR1-ir. The pattern of NTSR1-ir was exclusively cytoplasmic in 25/95 samples and exclusively nuclear in 7/95 (Tables 5 and 6).

Altogether, no statistically significant correlation could be found between NTSR1-ir and the GIST clinico-pathological features.

NTSR1 - but not Neurotensin (NT) - is expressed in the human GIST882 cell line

In the human GIST882 cell line, NTSR1 expression was confirmed by RT-PCR (Fig. S2A), and WB (Fig. S2B) while

![Figure 2. NTSR1-ir is present in a human GIST with KIT K642E mutation but not in normal human KIT-ir ICC.](image-url)
transcript of neurotensin/neuromedin N precursor (NT/N) was not detected by RT-PCR. The human astrocytoma cell line 1321N1 served as positive control (Fig. S2A).

**Discussion**

To the best of our knowledge, the distribution of NTSR1-ir in the muscularis propria of the gut had not been previously reported. We observed NTSR1-ir in the soma of myenteric

---

**Figure 3. NTSR1-ir in human GIST is irrespective to the mutation status.** NTSR1 and KIT immunohistochemistry on FFPE human TMA. A: Representative example of NTSR1-ir in a gastric GIST (left). NTSR1-ir was also present in adjacent myenteric plexus (arrows) (middle) while adjacent non-tumoral tissue (*) (right) exhibited only minimal background (non-specific) signal. B: Column 1 and 2: Representative examples of NTSR1-ir in KIT-ir GIST while (KIT negative) non-tumoral tissue exhibited only minimal (non-specific) background signal. Column 3: Example of a KIT negative GIST with PDGFRA mutation positive for NTSR1-ir. Scale bars in A and B: 20 microns. doi:10.1371/journal.pone.0014710.g003
neurons and in nerve fibers in the muscle layers, in both mouse and human gut, while the KIT-ir ICC and other cell types were not labeled.

Conversely, NTSR1-ir was consistently detected in the hyperplastic Kit-ir cells in the murine KIT641E GIST model and in all 95 human GIST investigated, irrespective of the presence of KIT-ir or KIT/PDGFRA mutation. The expression of NTSR1-ir in GIST, but not in normal ICC, contrasts with other markers recently reported in human GIST, which are generally also expressed in normal ICC [7,10,11].

We have identified three distinctive patterns of NTSR1-ir (nuclear; cytoplasmic; mixed) in GIST TMA but they could not be correlated with the recorded histopathological characteristic of the tumors. Nuclear localization of NTSR1 has been linked to cell responses evoked by intense and persistent agonist stimuli [20–23]. NT, the natural NTSR1 high-affinity ligand, is a gut hormone normally present in serum and surges upon feeding [24,25]. In tissues, NT can also be produced by tumoral cells [26] or by reactive cells in their vicinity [22,27–30], creating autocrine or paracrine activating loops, respectively. Hence, the variable proportions of

| No | Morphology | Primary site | Risk Assessment | Mutation Status | Size | Mitotic Figures | NTSR1-ir |
|----|------------|--------------|----------------|----------------|------|----------------|---------|
| 1  | Epithelioid | gastric      | moderate       | PDGFRA Exon 12 | 13 cm| 4/50 HPH       | mix     |
| 2  | Epithelioid | gastric      | low            | PDGFRA Exon 18 | 5.2 cm| 2/50 HPH       | mix     |
| 3  | Epithelioid | gastric      | moderate       | PDGFRA Exon 12 | 15 cm| 1/50 HPH       | nuclear |
| 4  | Spindle    | gastric      | moderate       | PDGFRA Exon 18 | 17 cm| 2/50 HPH       | nuclear |

doi:10.1371/journal.pone.0014710.t004

Figure 4. NTSR1-ir patterns in human GIST. Representative images of NTSR1-ir staining patterns encountered on GIST TMA: A: Nuclear staining. B: Cytoplasmic staining. C: Mixed pattern: NTSR1-ir present in both nucleus and cytoplasm of the tumor cells. D: Mixed pattern: nuclear and cytoplasmic NTSR1-ir patterns coexisting in adjacent parts of the tumor. Scale bar: 20 microns.
doi:10.1371/journal.pone.0014710.g004
nuclear and cytoplasmic NTSR1-ir observed in GIST TMA, possibly represents different levels of NTSR1 activation caused by a complex and dynamic interplay of various sources of ligand and possibly other factors. The precise origin of NTSR1 activation in individual GIST remains to be established. In the GIST882 cell line, the redistribution of NTSR1-ir upon stimulation by the specific NTSR1 agonist JMV499 suggests the presence of functionally responsive NTSR1 while the absence of NT/N precursor mRNA expression rule out an autocrine activation loop in that cell line.

High affinity NT binding sites have been found in various cancers, including Ewing’s sarcoma [31] and NTSR1 expression, driven by the Wnt/b-catenin pathway, is an early event in oncogenic transformation [22,23]. Sustained activation of NTSR1 leads to persistent activation of signaling pathways, including ERK1/2 [20], hence facilitating tumor growth and progression. NTSR1 has been associated with progression in lung, colon, prostate and breast epithelial cancers [29,30,32]. According to the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/), NTSR1 is also expressed in a variety of sarcoma. Therefore, NTSR1 expression appears to be linked to tumorigenesis in general and cannot be used as a diagnostic tool to distinguish GIST from other tumor types or to predict their risk of malignancy.

Nevertheless, the identification of NTSR1 expression in GIST but not in the KIT expressing ICC cells from which they derive, offers clinical perspectives that deserve further consideration. Firstly, NTSR1 can be targeted with radio-labeled NT analogues for whole body tumor imaging and possibly even for subsequent therapeutic interventions. Currently, 18F-Fluoro-deoxyglucose (18F-FDG) positron emission tomography (PET) is used for assessing tumor response to tyrosine kinase inhibitors in vivo [33–35]. However, 18F-FDG-PET cannot differentiate between GIST and other gastrointestinal malignancies including epithelial cancers and lymphoma and in some cases, 18F-FDG-PET fails to detect the relapse of GIST at an early time point [36]. An analogue based on NT (8–13) NT-XIX, has already been synthesized and characterized. Radioactivity clearance of NT-XIX analogue from healthy organs was faster than from tumors, resulting in improved tumor-to-tissue ratios and good SPECT/CT imaging [15]. NTSR1 in vivo imaging has already been successfully used in patients with ductal pancreatic adenocarcinoma [37]. Therefore NTSR1 in vivo imaging deserves full consideration in GIST.

NTSR1 may also be considered as a prospective direct therapeutic target. NT antagonists, such as SR48692, counteract the stimulatory effect of NT on tumor cells [22]. The influence of SR48692.21 on GIST proliferative characteristics thus deserves consideration.

Finally, NTSR1 could represent the gateway to introduce cytotoxic chemicals or expression vectors targeting the constitutively activated pathways into the cancerous cells [38–40].

| Clinicopathologic features | NTSR1-ir (n/total) | NTSR1-ir (n/total) | NTSR1-ir (n/total) |
|---------------------------|-------------------|-------------------|-------------------|
| Primary tumor site        | Nuclear | Cytoplasmic | Mix |
| Gastric                   | 2/34 | 7/34 | 24/34 |
| Small bowel               | 1/9 | 1/9 | 6/9 |
| Colon                     | 1/2 | 0/2 | 1/2 |
| Rectovaginal              | 0/1 | 1/1 | 0/1 |
| Disseminated              | 0/3 | 1/3 | 2/3 |
| Tumor morphology          | Nuclear | Cytoplasmic | Mix |
| Spindle                   | 4/35 | 7/35 | 22/35 |
| Epithelioid               | 0/14 | 3/14 | 11/14 |
| Risk category             | Nuclear | Cytoplasmic | Mix |
| Malignant - High          | 2/17 | 4/17 | 11/17 |
| Moderate - Low            | 2/21 | 5/21 | 14/21 |
| Very low - None           | 0/11 | 1/11 | 8/11 |
| Mitotic Figures           | Nuclear | Cytoplasmic | Mix |
| ≤5/50                     | 3/26 | 2/26 | 10/26 |
| >5/50                     | 1/17 | 7/17 | 18/17 |
| Mutation Status           | Nuclear | Cytoplasmic | Mix |
| KIT mutation              | 3/25 | 7/25 | 15/25 |
| KIT Exon 9 AY 502-503 duplication | 2/4 | 0/4 | 2/4 |
| KIT Exon 11 duplication   | 0/3 | 0/3 | 2/3 |
| KIT Exon 11 deletion      | 1/6 | 3/6 | 2/6 |
| KIT Exon 11 deletion - MYEV S52–S55 | 0/1 | 0/1 | 1/1 |
| KIT Exon 11 deletion - PMYE S51–S55 | 0/1 | 1/1 | 0/1 |
| KIT exon 11 V559D         | 0/5 | 0/6 | 0/6 |
| KIT exon 11 V560D         | 0/8 | 0/1 | 0/1 |
| KIT exon 11 V600D         | 0/1 | 0/1 | 0/1 |
| KIT exon 11 W557G         | 0/1 | 0/1 | 0/1 |
| KIT Exon 13 K542E         | 0/1 | 0/1 | 0/1 |
| PDGF mutation             | 0/9 | 3/9 | 6/9 |
| PDGFRA Exon 12 - V561D    | 0/2 | 1/2 | 1/2 |
| PDGFRA exon 12 deletion   | 0/1 | 0/1 | 0/1 |
| PDGFRA Exon 18 DB42Z      | 0/4 | 2/4 | 2/4 |
| PDGFRA Exon 18 DB42Y      | 0/1 | 0/1 | 0/1 |
| PDGFRA Exon 18 Ins-Del    | 0/1 | 0/1 | 0/1 |
| Wild type                 | 1/11 | 0/11 | 10/11 |

Table 5. NTSR1-ir on the Cleveland Clinic GIST TMA.

doi:10.1371/journal.pone.0014710.t005

| Clinicopathologic features | NTSR1-ir (n/total) | NTSR1-ir (n/total) | NTSR1-ir (n/total) |
|---------------------------|-------------------|-------------------|-------------------|
| Primary tumor site        | Nuclear | Cytoplasmic | Mix |
| Gastric                   | 2/28 | 8/28 | 18/28 |
| Female                    | 1/20 | 7/20 | 12/20 |
| Risk category             | Nuclear | Cytoplasmic | Mix |
| Malignant                 | 0/8 | 2/8 | 6/8 |
| High risk                 | 2/24 | 8/24 | 14/24 |
| Intermediate risk         | 1/8 | 1/8 | 6/8 |
| Low risk                  | 0/8 | 4/8 | 4/8 |
| Mitotic Figures           | Nuclear | Cytoplasmic | Mix |
| ≤5/50                     | 0/22 | 8/22 | 14/22 |
| >5/50                     | 3/26 | 7/26 | 16/26 |

doi:10.1371/journal.pone.0014710.t006

Table 6. NTSR1-ir on the SuperBiochips GIST TMA.
In conclusion, further studies are needed to substantiate the potential of NTSR1 for clinical interventions in GIST.

Supporting Information

Figure S1 Ntsr1-ir is expressed in Kit–ir cell clusters in the antrum of adult heterozygous KitWT/K641E mice but not in WT ICC. Representative epifluorescence images of Ntsr1-ir distribution in the adult mouse antrum: Ntsr1-ir (NL559, red) was observed in Kit-ir (Alexa 488, green) cell clusters (insert) in adult heterozygous KitWT/K641E mice, but not in WT littermates. Ntsr1-ir was also consistently found in the myenteric plexus (*). Fluorescence intensity plots along the yellow lines illustrate the respective distribution of NTSR1-ir (DyLight 549, red) and DNA (Hoechst, blue).

Found at: doi:10.1371/journal.pone.0014710.s001 (4.53 MB TIF)

Figure S2 NTSR1 is expressed in the human GIST882 cell line and responds to agonist stimulation. A: NTSR1 - not detected. C: Representative confocal microscopy images of NTSR1-ir patterns in GIST882 cells. Upper row: After overnight incubation in FBS free medium, a diffused cytoplasmic and nuclear NTSR1-ir (DyLight 549, red) was observed. Lower row: After stimulation with the NTSR1 agonist, JMV449 for 4 hours, NTSR1-ir strongly increased in the nucleus and in many cells, cytoplasmic NTSR1-ir exhibited a dot-like pattern. Scale bars: 20 microns. Fluorescence intensity plots along the yellow lines illustrate the respective distribution of NTSR1-ir (DyLight 549, red) and DNA (Hoechst, blue).

Found at: doi:10.1371/journal.pone.0014710.s002 (9.69 MB TIF)

Acknowledgments

We are indebted to Perrine Hagué and Huy Nguyen Tran for expert technical assistance and preparation of the figures, respectively. We are thankful to Dirk Tourwé and Tony Lahoute, Department of Organic Chemistry and In Vivo Cellular Imaging Center, respectively, Vrije Universiteit Brussels, Belgium for stimulating discussion regarding Ntsr1 in vivo imaging.

Author Contributions

Conceived and designed the experiments: PG CE JMV. Performed the experiments: SN MBD PG CE JMV. Analyzed the data: PG CE JMV. Contributed reagents/materials/analysis tools: BR. Wrote the paper: PG BR CE JMV.

References

1. Kitamura Y (2008) Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol 43: 499–508.
2. Liegl-Atzwanger B, Fletcher JA, Fletcher CD (2010) Gastrointestinal stromal tumors. Virchows Arch 456: 111–127.
3. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, et al. (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 10: 81–89.
4. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, et al. (2004) Kit-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28: 889–894.
5. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349.
6. Corless CL, Schroeder A, Griffith D, Town A, McGeevey L, et al. (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23: 5357–5364.
7. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, et al. (2004) Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 10: 4089–4093.
8. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, et al. (2004) Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 64: 5127–5131.
9. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, et al. (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of Kit or PDGFRA mutation status. Am J Pathol 165: 107–113.
10. Parkila S, Lasota J, Fletcher JA, Ou WB, Kivela AJ, et al. (2010) Carboxic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 23: 743–750.
11. Gomez-Pinilla PJ, Gibbons SJ, Bardelle MR, Lorincz A, Pozo MJ, et al. (2009) Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 296: G1370–G1380.
12. Chen H, Oredog T, Chen J, Young DL, Bardelle MR, et al. (2007) Differential gene expression in functional classes of interstitial cells of Cajal in murine small intestine. Physiol Genomics 31: 492–505.
13. Rubin BP, Antonescu CR, Scott-Brown JP, Comstock ML, Gu Y, et al. (2005) A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 65: 6631–6639.
14. Gromova P, Ralea S, Lefort A, Libert F, Rubin BP, et al. (2009) Kit K641E oncogene up-regulates Sprouty homolog 4 and trophectoderm glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumors. J Cell Mol Med 13: 1536–1548.
15. Garcia-Garaya E, Blauenstein P, Blanc A, Marc V, Tourre D, et al. (2009) A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumors. Eur J Nucl Med Mol Imaging 36: 37–47.
16. Hellemans J, Mortier G, De Paepa A, Speelman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19.
17. Mitretin M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70–83.
18. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, et al. (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5: Suppl 2: S1–S9.
19. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, et al. (2001) NTSR1 inactivation of the gastrointestinal stromal tumor c-KIT tumourprotein: biological and clinical implications. Oncogene 20: 5654–5658.
20. Toy-Miou-Leong M, Coral CL, Beaudet A, Rostene W, Forges P (2004) Receptor trafficking via the perineural recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation. J Biol Chem 279: 12636–12646.
21. Toy-Miou-Leong M, Bachelet CM, Pelaprat D, Rostene W, Forges P (2004) NT agonist regulates expression of nuclear high-affinity neurotensin receptors. J Histochim Cytochem 52: 335–345.
22. Souazé F, Dupuy S, Viardé-Foucault V, Breunety E, Atnous S, et al. (2006) Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res 66: 6243–6249.
23. Souazé F, Viardé-Foucault V, Roullet N, Toy-Miou-Leong M, Gompel A, et al. (2006) Neurotensin receptor 1 gene activation by the Trk/c-src/transforming pathway is an early event in human colorectal adenomas. Carcinogenesis 27: 708–716.
24. Blackburn AM, Bloom SR (1979) A radioimmunoassay for neurotensin in human plasma. J Endocrinol 93: 175–181.
25. Shaw C, Buchanan KD (1983) Intact neurotensin (NT) in human plasma: response to oral feeding. Regul Pept 7: 145–153.
26. Dong Z, Wang X, Zhao Q, Townsend CM, Jr., Evers BM (1998) DNA methylation contributes to expression of the human neurotensin/neuromedin N gene. Am J Physiol 274: G535–G543.
27. Thodorson-Norheim E, Oehg K, Rosell S, Bostrom H (1983) Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut. Gastroenterology 85: 881–889.
28. Meggiato T, Ferrara C, Tessari G, Plebani M, De Paoli M, et al. (1996) Serum neurotensin levels in patients with gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Semin Diagn Pathol 23: 70–83.
29. Carraway RE, Plona AM (2006) Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 27: 2445–2460.
30. Evers BM (2006) Neurotensin and growth of normal and neoplastic tissues. Peptides 27: 2424–2433.
31. Reubi JC, Waser B, Schaer JC, Lainsie JA (1999) Neurotensin receptors in human neoplasms: high incidence in Ewing’s sarcomas. Int J Cancer 85: 213–218.
32. Dupuy S, Viardé-Foucault V, Alfano M, Souazé F, Plou-Bureaux, et al. (2009) The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS ONE 4: e1223.
33. Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38: Suppl 5: S60–5.
34. Jager PL, Gietema JA, van der Graaf WT (2004) Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 25: 433–438.
35. Prior JO, Montemurro M, Orcurto MV, Michieli O, Luthi F, et al. (2009) Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27: 439–445.
36. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den AA, et al. (2005) Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 235: 892–898.
37. Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, et al. (2003) Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 44: 1649–1654.

38. Arango-Rodriguez ML, Navarro-Quiroga I, Gonzalez-Barrios JA, Martinez-Anguelles DB, Bannon MJ, et al. (2006) Biophysical characteristics of neurotensin polyplex for in vitro and in vivo gene transfection. Biochim Biophys Acta 1760: 1009–1020.
39. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, Anaya-Martinez V, Flores G, et al. (2006) Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 14: 857–865.
40. Martinez-Fong D, Navarro-Quiroga I (2000) Synthesis of a non-viral vector for gene transfer via the high-affinity neurotensin receptor. Brain Res Brain Res Protoc 6: 13–24.